The needs of premenopausal women with hypoactive sexual desire disorder (HSDD) are met by flibanserin (Generic Addyi). Patients with acquired and generalized HSDD might benefit from this since it contains a 5-HT receptor modulator.
This medication was given FDA approval in 2015, making it possible for premenopausal women to get effective therapy for hypoactive sexual desire disorder. Did you know this medicine was used as a replacement for an antidepressant in early trials? However, following more testing and refinement, it proved to be an effective method of dealing with hypoactive sexual condition.